COR vs RPRX
COR: Cencora is a critical link in the global healthcare supply chain, providing pharmaceutical distribution, commercialization services, and specialty drug support to ensure patients have access to life-saving medications. RPRX: Royalty Pharma is the leading acquirer of biopharmaceutical royalties, providing capital to the healthcare industry in exchange for long-term rights to drug revenue streams.
Side-by-side fundamentals
| Metric | COR | RPRX | Edge |
|---|---|---|---|
| Price as of 2026-08-06 close | $325.01 | $57.26 | |
| Market cap as of 2026-08-08 | $62.0B | $22.2B | |
| P/E as of 2026-08-08 | 23.30 | 40.06 | COR lower |
| PEG as of 2026-08-08 | 2.26 | 3.59 | COR lower |
| Net margin as of 2026-08-08 | +0.8% | +32.1% | RPRX higher |
| Gross margin as of 2026-08-08 | +4.0% | n/a | |
| Operating margin as of 2026-08-08 | +0.9% | +59.6% | RPRX higher |
| ROE as of 2026-08-08 | +104.4% | +12.3% | COR higher |
| ROA as of 2026-08-08 | +3.3% | +4.2% | RPRX higher |
| Debt / equity as of 2026-08-08 | 3.62 | 1.31 | RPRX lower |
| Revenue growth (YoY) as of 2026-08-08 | +5.1% | +10.0% | RPRX higher |
| Revenue CAGR (3y) SEC XBRL | +10.4% | +2.1% | COR higher |
| Dividend yield as of 2026-08-08 | +0.7% | +1.6% | RPRX higher |
| Dividend streak (yrs) SEC XBRL | 4 | 5 | RPRX higher |
| Beta as of 2026-08-08 | 0.57 | 0.40 | |
| 1-year return as of 2026-08-06 close | +14.5% | +54.3% | RPRX higher |
Fundamentals: market data, as of 2026-08-08. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-06.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.